ABSTRACT The immediate effects of intravenous diltiazem effects and short-term (4 weeks) of the oral drug on systemic and regional hemodynamics, cardiac structure, and humoral responses were evaluated by previously reported methods in nine patients with mild-to-moderate essential hypertension and in one patient with primary aldosteronism. Diltiazem was first administered in three intravenous doses of 0.06, 0.06, and 0.12 mg/kg, respectively; patients were then treated for 4 weeks with daily doses ranging from 240 to 360 mg (average 300 mg). 108-113, 1986. DILTIAZEM is a benzothiazepin derivative calcium antagonist widely used in the management of angina pectoris and currently under investigation for patients with hypertension.1`3 Its antihypertensive effect appears to result from inhibition of calcium entry into vascular smooth muscle, consequently producing arteriolar dilatation. The precise hemodynamic effects on systemic and regional blood flow are not totally clear. The present study was performed to evaluate the immediate and short-term hemodynamic effects of diltiazem in patients with mild-to-moderate hypertension.
DILTIAZEM is a benzothiazepin derivative calcium antagonist widely used in the management of angina pectoris and currently under investigation for patients with hypertension.1`3 Its antihypertensive effect appears to result from inhibition of calcium entry into vascular smooth muscle, consequently producing arteriolar dilatation. The precise hemodynamic effects on systemic and regional blood flow are not totally clear. The present study was performed to evaluate the immediate and short-term hemodynamic effects of diltiazem in patients with mild-to-moderate hypertension.
Methods
Ten patients (eight men and two women; seven black and three white) with mild-to-moderate hypertension, including one white man with primary aldosteronism, were the subjects of this report. The remainder, therefore, had essential hypertension.
Their mean age was 47 + 11 (range 34 to 69) years. The patients had either never received antihypertensive therapy previously or had all antihypertensive medications discontinued at least 4 weeks before entry into the study.
Clinical evaluation for secondary forms of hypertension had failed to demonstrate a primary cause of hypertension in all patients except the one with primary aldosteronism who received spironolactone throughout the study.
Patients were included in the study only if their diastolic pressures were equal to or higher than 90 mm Hg and less than 120 mm Hg on at least two consecutive outpatient visits during the 2 weeks before diltiazem therapy was instituted.
After at least 2 weeks without antihypertensive therapy the patients were given a placebo for another 2 weeks. Informed written consent, previously approved by our institutional human study committee, was obtained from the patients after they were provided with a detailed description of the protocol.
Hemodynamic assessment. At the end of the second week of the placebo phase, patients were studied in the hemodynamic laboratory after an overnight fast. By a modified Seldinger technique, catheters were inserted into a brachial artery and an antecubital vein and advanced to the shoulder level.4 Continuous recordings of arterial and venous pressures were obtained simultaneously with the electrocardiogram (lead II). Cardiac output was determined at least in duplicate, usually in triplicate, using indocyanine green dye (5 mg each injection). Resting supine hemodynamic measurements were obtained before and after sequential intravenous bolus administration of diltiazem at doses of 0.06, 0.06, and 0.12 mg/kg. In addition, hemodynamic responses to upright tilt (48 degrees), isometric exercise (handgrip, 30% of maximum), and Valsalva maneuver were measured before and after the final intravenous dose of diltiazem. The same hemodynamic measurements were obtained after 4 weeks of diltiazem therapy.
M mode echocardiograms were recorded before and after the third intravenous injection of diltiazem as well as after 4 weeks of oral diltiazem therapy. The techniques for left ventricular visualization have been described previously.5 Posterior and septal wall thicknesses and systolic and diastolic dimensions were measured by three independent observers using the same five consecutive cycles. Left ventricular mass was calculated according to the formula of Bennett and Evans. 6 Echocardiographic estimates of left ventricular end-systolic and end-diastolic volumes were calculated by the method of Teichholz et al. 7 Renal plasma flow and plasma volume were determined by the single injection clearance of 131j-paramino hippurate and RISA-1251, respectively.4 Splanchnic blood flow was obtained from the plasma clearance of injected indocyanine green dye (50 mg).' Renal and splanchnic vascular resistance were calculated by dividing mean arterial pressure by the respective regional blood flows. Glomerular filtration rate was determined from 24 hr creatinine clearance, and filtration fraction was obtained by dividing glomerular filtration rate by renal blood flow.
Total blood volume and red cell mass were estimated from plasma volume according to the formula8:
where TBV is total blood volume, PV is plasma volume, Hct is the peripheral hematocrit, and 0.91 is the correction factor for total body hematocrit.
Plasma renin activity and catecholamine levels were determined by the methods of 
Results
Of the 10 patients, one did not return to undergo hemodynamic evaluation after 4 weeks of diltiazem therapy. Important side effects were not observed either immediately after the intravenous dose or during short-term oral diltiazem therapy.
Intravenous diltiazem. (table 3) .
Discussion
The results of this study demonstrate that after intravenous diltiazem there was an immediate dose-related reduction in mean arterial pressure produced by a fall in total peripheral resistance that was most likely associated with a reflex increase in heart rate and cardiac output, although plasma catecholamine levels did not change. Previous studies have found similar reSUltS.2' 13 Safar et al.'4 observed that similar reflexive sympathetic adjustments disappeared 25 min after intravenous diltiazem. They hypothesized that this reflex cardiac stimulation was dampened either by the action of diltiazem on baroreceptor function'5 or by a calcium-dependent release of neurotransmitter from postganglionic nerve endings.'6 However, they also noted that the increased heart rate could have resulted from a direct effect on larger arteries. Diltiazem seems to have different effects on small and large arteries, dilating the arterioles and reducing total peripheral resistance, but having no effect on large arteries. 14 We also calculated changes in large arterial distensibility by dividing arterial pulse pressure by stroke volume and confirmed the earlier report demonstrating that diltiazem had no immediate effect on large arterial distensibility. We also extended that observation by demonstrating that the compound also had no effect on distensibility after 4 weeks of therapy (0.71 ± 0.08; 0.54 + 0.07, and 0.63 ± 0.07, before treatment, after intravenous drug, and after 4 weeks on oral drug, respectively).
The significant immediate reduction in mean arterial pressure observed after intravenous diltiazem persisted throughout the 4 week treatment period, although the significant fall in total peripheral resistance did not continue as heart rate and cardiac index returned to pretreatment levels. Interestingly, those patients who continued to demonstrate a significant fall in total peripheral resistance all had pretreatment plasma renin activity of 1.2 ng/ml/hr or less, and those with greater plasma renin activity failed to demonstrate this response even though their pressures remained controlled.
These results are in agreement with previous reports demonstrating greater effectiveness of calcium entry-blocking drugs in patients with lower plasma renin activity. '7' 18 In this regard it was of interest that the patient with the greatest reduction in arterial pressure in our study had primary aldosteronism; he demonstrated a 20% fall in mean arterial pressure and a 15% reduction in total peripheral resistance. Guthrie et al. 19 and Millar et al. 20 have described impairment of adrenal steroidogenesis after calcium channel-blocker therapy in normal subjects. Such an effect could explain the greater blood pressure reduction in our patient with primary aldosteronism. However, his plasma aldosterone levels increased from 72 to 120 and 104 ng/dl after intravenous drug and 4 weeks of oral therapy, respec- 
